Study and analysis of the coagulation factors and their natural inhibitors levels in apheresis derived platelet concentrate units over a five-day storage period

Amit A. Pawar, Amit K. Biswas, Rounak Dubey, Sujay Bhowmik


Background: The possibility of utilizing clotting factors in the plasma phase of apheresis platelet concentrates, as a supplement to the standard FFP transfusion for clotting factor replacement needs to be explored. In this study, it was proposed to assess the effect of storage on clotting factors and inhibitors in stored apheresis platelet concentrates. This would give an insight into the hemostatic potential of the plasma phase of the apheresis platelet concentrates.

Methods: This study was conducted on a sample size of 45 apheresis platelet concentrate units harvested on Amicus cell separator. Basic coagulation workup along with various coagulation factors and their natural inhibitors were studied in the apheresis platelet concentrates on day ‘0’ and day ‘5’ of the collection.

Results: Prothrombin time and activated partial thromboplastin time of the apheresis platelet concentrates was increased on day ‘5’ of the collection but were within the normal range. Fibrinogen, Factor XII, and VWF: Ag showed an increase on day ‘5’ of collection. Protein C, protein S activity, and antithrombin decreased on day ‘5’ of collection. Also, Factors II, VII, IX, X, XI decreased on day ‘5’. The highest fall in activity was seen in the case of Factors V and VIII. Despite the fall, all the clotting factors were maintained within their normal range.

Conclusions: Although the activity of most of the coagulation factors showed a decrease, it was maintained within their normal range and efficacy. Therefore, a reasonable hemostatic potential of the clotting factors is expected to be maintained in apheresis platelet concentrates after a storage period of five days at room temperature.


Apheresis platelet concentrates, Coagulation factors, Natural inhibitors

Full Text:



Shinagare SA, Angarkar NN, Naniwadekar MR. An audit of fresh frozen plasma usage and effect of fresh frozen plasma on the pre-transfusion international normalized ratio. Asian J Transfus Med. 2010;4(2):128-32.

British Committee for Standards in Haematology. Guidelines for the use of fresh-frozen plasma, cryoprecipitate, and cryosupernatant. Br J Haematol 2004;126:11-28

Standards for Blood Banks and Transfusion Services. 24th ed. Bethesda, MD: American Association of Blood Banks; 2006.

British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10-23.

Hess JR. Conventional blood banking and blood component storage regulation: opportunities for improvement. Blood Transfus. 2010;8:9-15.

Yun SH, Sim EH, Goh RY. Platelet activation: the mechanisms and potential biomarkers. BioMed Research International 2016;2016:9060143.

Weiss D, Franke D, Strasser E. von Willebrand factor, clotting factors and inhibitors in apheresis platelet concentrates. Transfusion. 2014;54:633-9.

Cookson P, Lawrie A, Green L. Thrombin generation and coagulation factor content of thawed plasma and platelet concentrates. Vox Sanguinis. 2015;108:160-8.